Cartilage-derived retinoic acid-senstive protein
Alternative Names: Melanoma inhibitory activity; MIALatest Information Update: 02 Oct 2021
At a glance
- Originator Scil Technology
- Class
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cartilage disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cartilage-disorders in Europe
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cartilage-disorders in USA
- 16 Jan 2008 Cartilage-derived retinoic acid-sensitive protein (CD-RAP) licensed to Pfizer Inc. worldwide